<html>
<head>
</head>
<body>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;"><b>International
Initiatives Assisting Push
Biotechs Like Nuvilex
(</b><b>NVLX</b><b>)
Further</b></span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;"><b>Are you passing the
trend?</b></span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;">The N_a_s_d_a_q Biotechnology Index has
fundamentally doubled the
revenue of the benchmark S&P 5-0-0 index in the
first six months of this year with
rewards about thirty percent.
Abroad, biotech is just as popping. Half of
the top ten biggest gainers of
Japan’s J_A_S_D_A_Q index are biotechnology
shares. Japan’s Prime Minister Shinzo Abe’s
Cabinet is predicted to bring
changes of the
Pharmaceutical Affairs Law to the country’s Parliament on Jun
27th to continue to change the
country’s laws to rush biotechnology R&D initiatives of the country. The
United States approved the
“FDAs Safety and Innovation
Act” into law last July, beckoning
the country’s pains to
hasten the pace to market of
novel d-r-u-g-s that touch areas of
huge unmet medical need.
Eventually, the cry for
new therapeutics is reverberating
around the earth and governments are
striving to answer the call,
creating a strong
hunger for investments in biotech
companies.</span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;">This certainly helps
explain the rise in biotech stocks
worldwide as possible investing interest is
spiking again, inc. that in <strong>N u v i le
x, Inc</strong>.
</u></b><b><u>(</u></b><b>N V L
X</b><b><u>)</u></b>, a biotechnology
organization which has
revealed that its pancreas can_cer
treatment utilizing its live-cell encapsulation
technology was able to outperform past
outcomes of Gemzar, one of the best-selling
can_cer d r u g s ever. In a Level
Two trial, N u v i le x’s technology was
used to encapsulate cells capable of activating
ifosfamide, a long-used anti-can_cer d r u g, to its
can_cer-killing form, and then the encapsulated cells were
placed in the blo_od supply near the pancreas,
and thus the tumor itself, in patients with advanced
inoperable pancreas can_cer. After implantation of the encapsulated
cells, ifosfamide was administered intravenously.
When the results were compared to historical
information for Gemzar, Nuvilex’s therapy ended in a
average survival rate that was double that
previously stated for Gemzar
and the one-year survival period was 200 percent
greater!</span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;">Even more striking, only one-third
of the regular dose was utilized in the Nuvilex-treated patients to
provide such strong
outcomes, effectually
minimizing the seriousness and
frequency of side effects that are
typically connected
with chemotherapy. </span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;">Adding extra
credence to the potential of N u v i le
x, the entity’s
proprietary live-cell encapsulation technology is
an adjustable platform that reaches
far past the convincing
figures created from the pancreas
can_cer research. This live-cell encapsulation technology, in
preclinical studies, has shown
capability as a foundation on which
therapies for a wide array of
indications such as can_cers of numerous
beginnings and other enervating
dis_ease, like dia-betes, may be built.</span></p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;">The trend of nations
world-wide to hold to continue to the time-consuming
and expensive controlling process to bring
new treatments to market that has
been in place for decades is hitting a wall. As a
outcome, major nations are
evaluating their d-r-u-g sanction
procedures and timelines and will likely bring about
important modifications to
them. In turn, this brings a sense of
importance to investors to take a
perceptive look where
important short-term and long-term
returns live in the biotechnology
business. Judging by
growing biotech investments and
speedy returns; the question
is…Are you overlooking the
trend?<br /><br />The use of research materials
circulated by the auth.or is done at your own
risk. You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed
herein. The author has not been rewarded by any entity in connection with
the distribution of these materials. You should
presume that as of the date of this report or letter, the author,
possibly along with or through our owners, affiliates, employees and/or
consultants, (collectively referred to as the
author) has a position in all company shares (and/or options of the shares)
covered herein that is consistent with the position set forth in our
report. In connection with NVLX, the author has taken a long position.
Following the distribution of any report or letter, the
author plans to continue engaging in trnsactns in the secu rity
covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
procure or trade all or part of our position at any time without notice.
This practice could end in our trading securities at any time before,
during, and/or after the disbursement of this report.<br
/><br /><a
href="http://cluster.afrikamangoplus.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=146"><span
style="font-size: small; font-family: arial, helvetica,
sans-serif;"></span></a><a
href="http://http://cluster.afrikamangoplus.com/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=146">List
removal</a></span><br />260
Madison Ave, 8th Fl., NY,
NY 10016 United States</p>
<p><span style="font-family: arial, helvetica, sans-serif; font-size:
small;"><br /> </span></p>
<p> </p>
<p> </p>
<img
src="http://cluster.afrikamangoplus.com/open.php?M=6588707&L=54&N=146&F=H&image=.jpg"
height="1" width="10"></body>
</html>